Study of INBRX-109 in Conventional Chondrosarcoma

Inclusion Criteria:

1. Conventional chondrosarcoma, unresectable (=inoperable) or metastatic.

2. Measurable disease by RECISTv1.1. Note: Tumor lesions located in a previouslyirradiated (or other locally treated) area will be considered measurable, providedthere has been clear imaging-based progression of the lesions since the time oftreatment.

3. Radiologic progression of disease per RECISTv1.1 criteria within 6 months prior toscreening for this study.

4. Adequate hematologic, coagulation, hepatic and renal function as defined perprotocol.

5. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.

6. Estimated life expectancy of at least 12 weeks.

7. Availability of archival tissue or fresh cancer biopsy are mandatory.

Exclusion Criteria:

1. Any prior exposure to DR5 agonists.

2. Allergy or sensitivity to INBRX-109 or known allergies to CHO-produced antibodies.

3. Non-conventional chondrosarcoma, e.g., clear-cell, mesenchymal, extraskeletalmyxoid, myxoid, and dedifferentiated chondrosarcoma.

4. Prior or concurrent malignancies. Exception: Patients with a prior or concurrentmalignancy whose natural history or treatment does not have the potential tointerfere with the safety or efficacy assessments.

5. Chronic liver diseases. Exception: Patients with fatty liver disease are acceptableas long as adequate hepatic function as defined in the inclusion/exclusion criteriais confirmed.

6. Evidence or history of multiple sclerosis (MS) or other demyelinating disorders.

7. Other exclusion criteria per protocol.